Medinol Announces Appointment Of Harvey J. Berger, M.D., As Executive Chairman Of Medinol US

PARSIPPANY, N.J. and TEL AVIV, Israel, Feb. 16, 2017 /PRNewswire-USNewswire/ -- Medinol, a global interventional cardiology device company, today announced the appointment of Harvey J. Berger, M.D., founder and past Chairman and Chief Executive Officer of ARIAD Pharmaceuticals, Inc., to the newly created position of Executive Chairman of Medinol US Inc., effective immediately.  Dr. Berger, 66, will join Medinol's global management in the areas of business development, global strategy, new business and technology initiatives and efforts to expand operational efficiency as the company evolves worldwide.  He will work with Medinol's core business of interventional cardiovascular devices, as well as its new businesses developing sub-millimeter implantable sensors, unique percutaneous aortic valves and other complementary products.

Dr. Judith Richter, Chief Executive Officer of Medinol, stated, "We are pleased and privileged to add to our management team talent like Dr. Berger with his capabilities and experience.  I am confident that his addition to our executive leadership will help us develop further and serve larger populations with different medical conditions with higher efficiency. Dr. Berger, a physician-scientist and biotechnology business-leader, brings over 35 years of professional experience to Medinol following successful academic and business careers in cardiology, oncology, and life sciences." 

"I am honored to join Medinol as Executive Chairman of Medinol US Inc. and work closely with Judith and Kobi Richter, the founders of Medinol, and its highly committed and capable employees in Israel and the U.S.  Judith and Kobi have offered me an extraordinary opportunity to help them and other company leaders grow Medinol into the preeminent medical device and technology company they should be.  The extensive intellectual-property portfolio and novel technologies under development at Medinol extend far beyond its initial focus on novel coronary artery stents.  I anticipate that these will contribute directly to Medinol's continued innovation, future products and commercial success as an industry leader," stated Dr. Berger.  Since founding ARIAD in 1991 through his retirement in 2015, Dr. Berger led the company's growth from a start-up to an integrated commercial global-oncology company that serves patients worldwide, and prepared it for the acquisition by Takeda.  From 1986 to 1991, Dr. Berger held senior-management positions at Centocor, Inc., including executive vice president and president of the research and development division.  

Dr. Berger also held senior academic and administrative positions, including as a tenured professor, at Emory University, Yale University and the University of Pennsylvania, and he was an Established Investigator of the American Heart Association.  He received an M.D. degree from Yale School of Medicine.

About Medinol

Medinol Ltd., headquartered in Israel, with U.S. commercial offices of Medinol US Inc. in Parsippany, NJ, is dedicated to the science of cardiovascular intervention.  For over 20 years, its in-house research, development and manufacturing have continuously raised the bar for quality and performance of stenting systems. In 2014, Medinol established its first sales office in the U.S. and launched its first product sold directly to hospitals, a bare metal stent called NIRxcell™.  With over two million stents deployed to date, Medinol's cutting edge cardiovascular intervention technology continues to demonstrate extraordinary clinical results, and their products constantly stretch the limits of innovation. 

For more information, go to www.medinol.com.

SOURCE Medinol

Related Links

http://www.medinol.com/